)
Visual
test
Scibase
Scibase (SCIB) investor relations material
Scibase Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary13 Mar, 2026
Executive summary
Net sales for Q4 2025 reached SEK 12.5 million, up 45% year-over-year; full-year sales grew 36% to SEK 40.5 million, driven by strong US and German markets and expanded collaboration with Castle Biosciences.
US sales surged 148% for the year and 84% in Q4, with Germany also showing double-digit growth; electrode sales volume increased 38% for the year.
Gross margin declined to 63.0% in Q4 and 67.0% for the year, impacted by currency effects, production ramp-up, and low-margin deliveries to Castle Biosciences.
Loss after tax widened to SEK 87.1 million for the year, with negative cash flow from operations of SEK 84.6 million.
Financing strengthened through a SEK 80 million rights issue and a SEK 20 million loan from Castle Biosciences.
Financial highlights
Q4 net sales: SEK 12.5 million (+45% y/y); full-year: SEK 40.5 million (+36% y/y).
Q4 gross margin: 63.0% (vs. 68.5% prior year); full-year: 67.0% (vs. 71.0%).
Q4 loss after tax: SEK 25.3 million; full-year loss after tax: SEK 87.1 million.
Cash and cash equivalents at year-end: SEK 22.6 million.
Electrode sales: 28,634 units in Q4 (+67% y/y); 86,180 units for the year (+38% y/y).
Outlook and guidance
Expectation of continued strong growth in the US and Germany, with reimbursement decisions anticipated in 2026.
Gross margin projected to recover in H2 2026 as production capacity utilization improves.
Ongoing expansion in the skin barrier segment, with new clinical studies and product launches planned.
Status of US reimbursement and payer discussions
Impact of Castle deliveries on gross margins
Clinical results for AD prediction in newborns
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Scibase
- Sales up 23% in Q3, margin down, with new financing and expanded US partnership fueling growth.SCIB
Q3 20257 Nov 2025 - Strong US growth and Castle Biosciences deal drive 32% sales increase, despite higher losses.SCIBQ2 202519 Aug 2025
- Q3 net sales up 16% and gross margin hit 75.7%, with SEK 81.8m raised for future growth.SCIBQ3 202413 Jun 2025
- Q2 sales up 31% with improved margins, but losses widened amid US expansion and new investments.SCIBQ2 202413 Jun 2025
- Strong sales growth and US expansion offset by higher losses; financing secured for continued growth.SCIBQ1 20255 Jun 2025
- Record US sales and capital raise drive SciBase growth, but losses widen.SCIBQ4 20245 Jun 2025
Next Scibase earnings date
Q1 20267 May, 2026
Scibase
Next Scibase earnings date
Q1 20267 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage